Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults...
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report...
Communiqué de presse : La FDA accorde un examen prioritaire à la demande de licence de produits biologique relative à Dupixent® pour le...
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Janvier 2024 Informations relatives au nombre total de droits...
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU) Japan first in the world to approve...
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS Phase 2 data published...
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.